Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation

This publication has 16 references indexed in Scilit:

• Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
  Blood, 2003
• Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
  Critical Care Medicine, 2003
• High plasma fibrinogen level is associated with poor clinical outcome in DIC patients
  American Journal of Hematology, 2002
• Disseminated Intravascular Coagulation in Sepsis
  Seminars in Thrombosis and Hemostasis, 2001
• Coagulation Blockade Prevents Sepsis-induced Respiratory and Renal Failure in Baboons
  American Journal of Respiratory and Critical Care Medicine, 2001
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001
• Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation
  Thrombosis and Haemostasis, 2001
• Disseminated Intravascular Coagulation
  New England Journal of Medicine, 1999
• Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
  Chest, 1992
• Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation
  Chest, 1992